Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $100 price target.
October 31, 2024 | 10:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Intra-Cellular Therapies and maintained a $100 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $100 price target by a reputable analyst suggests a positive outlook for ITCI. This can boost investor confidence and potentially lead to a short-term increase in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100